Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II osimertinib study in EGFR-mutant NSCLC after isolated CNS progression or later systemic progression (WJOG12819L)
jRCT2080225210Phase 2Completed
- Sponsor
- Kazuhiko Nakagawa (Coordinating Investigator)
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Kazuhiko Nakagawa (Coordinating Investigator). Started May 2020; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225210.